sign in sign up
<<
Home , Period 5 element

Product chemistry

Trade name: Silvclean

Silvclean is a cost effective, universally applicable gas adsorbent, odor controller, fly and maggot repellant.

Formulation type: Liquid suspension

Active ingredients (A.I.): Ions embedded in a matrix of near Nano as a suspension.

Common name: silver (Ag+)

Name CAS # CONTENTS Colloidal Silver 9015-51-4 50-100 ppm ≤ 400 nm size particle suspension

Synonyms for Silver: Ag, Argentum, Silver, Silver Particles, Ultra-fine Silver, Nano Silver, Silber (German), Silver ,

Pure Silver Characteristics:

Molecular weight: 107.87

Molecular Formula: Ag

Boiling point: 2162 °C for pure silver

Melting point: 961.78 °C for pure Silver

Heat of Decomposition: Currently not available

Reid Vapor Pressure: Currently not available

Bulk Density : 10490 kg/m³ as pure silver

Solubility in water and organic solvents Silver is insoluble. In this product is in colloidal form and the particles are nano.

Viscosity (liquid form): Not Pertinent

PURE SILVER

CLASSIFICATION:  Silver is a D, 11, 5 element.  The number of electrons in each of Silver's shells is 2, 8, 18, 18, 1 and its electronic configuration is [Kr]4d10 5s1.  In its elemental form silver's CAS number is 7440-22-4.  The silver has a radius of 144.5.pm and it's is 144.pm.

CAS NO.: 7440-22-4

EINECS Number: 231-131-3

RTECS Number: VW3500000

Hazards identification

HMIS RATING Health: 0 Flammability: 0 : 1

NFPA RATING Health: 0 Flammability: 0 Reactivity: 1

Colloidal Silver:

CAS#: 9015-51-4

RTECS: Not available.

TSCA: TSCA 8(b) inventory: No products were found.

CI#: Not available.

Synonym: Silver nucleate; silver protein, mild; Silvol; mild protargin; silver , colloidal

Chemical Name: Colloidal Silver

Chemical Formula: Not available.

Appearance, color, odor, physical state: Nano particles

Particle Size: ≤ 400 nm

Toxicological Data on Ingredients: Colliodal Silver LD50: Not available. LC50: Not available.

Federal and State Regulations: TSCA 8(b) inventory: No products were found.

Other Regulations: Not available.

Other Classifications:

WHMIS (Canada): Not controlled under WHMIS (Canada).

Protective Equipment: None

Health Hazarads

Routes of Entry:

1. Inhalation: None.

2. Skin: None.

3. Ingestion: None.

Signs and Symptom of Exposure: None

Medical Conditions Generally Aggravated by Exposure: None

Acute Health Hazard: None

Chronic Health Hazard: None Carcinogenicity: Composition: content, solvent, additive: No Solvents

Combustion Molar Ratio (Reactant to Product): Not Pertinent

Corrosiveness: Non-corrosive

Materials to be avoided: Alkaline substances,

Foam when mixed water: NA

Stability at 50 degrees C: Stable under ordinary conditions of use and storage.

Hazardous Decomposition Products: Metal oxide fume.

Hazardous Polymerization: Will not occur.

Incompatibilities: Silver is incompatible with acetylene, ammonia.

Major Contaminants that contribute to instability: Light, Heat, Alkalies

Storage and shelf life:  Store in a dry location away from heat and out of direct sunlight in containers fitted with a safety valve or vent. Storage temperature: <104°F (40°C).  Store in an area away from acids, bases, , metal salts, reducing agents, organic materials or flammable substances.  Do not store near or expose to heat sources (ie: steam pipes, radiant heaters, hot hair vents or Welding sparks)  Rotate inventories - first in, first out.

First aid

If in eyes:  Hold eye open and rinse slowly and gently with water for 15-20 minutes.  Remove contact lenses, if present, after first 5 minutes, then continue rinsing eye.  Call a poison control center or doctor for treatment advice.

If on skin or clothing:  Take off contaminated clothing. Rinse skin immediately with plenty of water for 10-15 minutes.  Then use non-abrasive soap and large amounts of water for another 10-20 minutes.  Be particularly careful to clean folds, crevices, creases and groin.

Serious Skin Contact:  Wash with plenty of water. Seek medical attention.

If swallowed:  Have person sip a glass of water if able to swallow.  Do not induce vomiting unless told to do so by the poison control center or doctor.

If inhaled:  Move person to fresh air. If person is not breathing, call 911 or an ambulance, then give artificial respiration, preferably by mouth-to-mouth, if possible.  Call a poison control center or doctor for treatment advice.

Notes to Physician:  Modest irritation is only expected effect and should have no serious consequences since Silver is a with low and is beneficial in all respects.  If large quantities are ingested, gastrointestinal irritation is to be expected.  No systemic effects are expected.  Have the product container or label with you when calling a poison control center or doctor, or going for treatment.

Efficacy data from other countries: Not Available

Safe in use: GENERALLY RECOMMENDED AS SAFE

Toxicology

Modern Colloidal Silver applications

Numerous ingested toxicity studies have been completed on nano-silver products. Some of the studies are outlined below:  Independent LD-50 tests on animals at levels equivalent to approximately 200 times the normal internal use adult dosage were found to be non-toxic to the animals.  A 28-day bird flu study completed by a U.S. NIH virology lab also included a toxicity study in which the animals were fed levels of the nano-silver at 10-200 times the normal dosage daily.  The ASAP nano-silver products were found to be non-toxic to the animals in the long term study.  A separate medical college study tested the ingestion of nano-silver product in animals at levels of 0.5 ml, 1.0 ml, and 1.5 ml daily for 28 days, and again found the product completely non-toxic to the animals.  An Indian (WHO approved) lab tested the ASAP nano-silver products for toxicity in a mouse-model study at levels of 50, 500, 5,000 mg/kg.  The product was again found to be completely non-toxic to the animals at all levels tested in the Indian study.  A peer-reviewed preliminary HIV Human study found that the oral ingestion of 2 ounces daily for four months of the 10 ppm ASAP nano-silver product, had no negative effect on the seven human patients.  A U.S. Congressional Testimony outlines the use of the ASAP nano-silver product at between 0.5-1.0 ounce daily use at 10 ppm, for human use of the product against malaria and other human ailments (120+ cases).  In all cases, no negative effects were reported from any of the four hospitals and clinics that tested the product, by either external or internal use (mostly internal use).  Silver has been used for generations in goblets, silverware, and other food areas because of the belief that it inhibits diseases.  In more recent times, the former Soviet Union used silver to sterilize recycled water on their space shuttles.  Many international airlines use silver water filters to ensure safe drinking water for passengers. The Swiss have approved use of these filters in homes and offices. Some US city municipalities use silver in treatment of sewage and is sometimes used to purify swimming pool water to avoid the stinging of the eyes that causes. CS also purifies drinking water.  Silver has become the latest agent in the fight against airborne toxins, as well other industrial poisons, in the Japanese work place.  Dr.Henry Crooks (Use of Colloids in Health-Disease) found that silver in the colloidal state is highly germicidal, quite harmless to humans and absolutely non-toxic.  Dr. Becker's experiments conclude that silver works on the full spectrum of pathogens without any side effects or damage to any part of the body.  Due to its properties, silver has also been incorporated in filters to purify drinking water and clean swimming pool water (Agency for Toxic Substances and Disease Registry [ATSDR] 1990, cited in World Health Organization [WHO] 2002).

ORAL LD50:  LD50 is 2854 mg/Kg of animal body weight  The silver level is well below 180 micrograms / person / day permitted by W.H.O.  Hence it is safe for human as well as aquatic and terrestrial animal life.

Genetic toxicity in vitro: - In vitro tests did not show mutagenic effects

Effect on suckling and lactating dams: Not determined

Neurotoxicity in Hens: No Neuro-toxic effect at the recommend dosage

Residue and effect on human: Safe work practices should always be followed.

Residue data from other countries: Not Available

Fatty tissue accumulation: Not pertinent. Not determined. No dietary exposure is expected from the uses of Silvclean since no food or feed uses are registered.

Max Residue Limit (MRLs): Not Pertinent

Acceptable daily intake (ADI): None determined. No dietary exposure is expected from the uses of Silvclean since no food or feed uses are contemplated for registration.

Effect on environment

Effect on natural enemies: Not Available

Environment fate: Not suspected to be an environmental toxin.

Products of Biodegradation: Possibly hazardous short term degradation products are not likely.

Toxicity of the Products of Biodegradation: The product itself and its products of degradation are non toxic.

Special Remarks on the Products of Biodegradation: Not available.

Volatility: Low

Absorption in the soil: It has minimal tendency to bind to soil or sediment

Leaching:-

GUS leaching potential index: Not pertinent

Soil degradation and Hydrolysis: Not available

Photolysis DT50 (days) at pH 7: Photolysis is part of the light-dependent reactions of photosynthesis.

Effect on non-target organisms

Effect on bird, bees and wild animals: Not available

Effect on fish, aquatics: Not available

Effect on natural enemies: Not Available

Web References: www.healthcarewasre.org www.noharm.org www.medwastecontest.org www.cleanmed.org www.cdc.gov/exposurereport www.telmedpak.com.waste_disposal http://www.indmedica.com/journals.php?journalid=11&issueid=98&articleid=1324&action=article. http://envfor.nic.in/legis/hsm/biomed.html - Website of the MINISTRY OF ENVIRONMENT & FORESTS.

References  Anderson RL, Mackel DC, Stoler BS, Mallison GF. Carpeting in hospitals: An epidemiological evaluation. J Clin Microbiol 1982;15:408-15.  Biomedical Waste Management - An Emerging Concern in Indian Hospitals.  Blaser MJ, Smith PF, Cody HJ, Wang WL, LaForce FM. Killing of fabric-associated bacteria in hospital laundry by low temperature washing. J Infect Dis 1984;149:48-57.  Centers for Disease Control. Viral hemorrhagic fever: initial management of suspected and confirmed cases. MMWR (suppl) 1983;32: 275-405.  Christian RR, Manchester JT, Mellor MT. Bacteriological quality of fabrics washed at lower-than-standard temperatures in a hospital laundry facility. Appl Env Microbiol 1983;45:591-7.  Favero MS. Chemical disinfection of medical and surgical materials. In: Block SS, ed. Disinfection, sterilization and preservation. 3rd ed. Philadelphia: Lea and Febiger, 1983;469-92.  Fed Reg June 22, 1984, 29 CFR 1910, Occupational Exposure to Ethylene Oxide.  Garner JS, Simmons BP. Guideline for isolation precautions in hospitals. Infect Control 1983;4:245-325.  Govt of India, Ministry of Environment and Forests Gazette notification No 460 dated July 27, New Delhi:1998:10-20  Hughes HG. Chutes in hospitals. J Can Hosp Assn 1964;41:56-7.  Institute for Health Policy Analysis, Georgetown University Medical Center. Proceedings of International Conference on the Reuse of Disposable Medical Devices in the 1980's. March 29-30, 1984. Washington, D.C.  Jacobs C, Brunner FP, Chantler C, et al. Combined report on regular dialysis and transplantation in Europe VII. 1976. Proc Eur Dial Transplant Assoc 1977;14:3-69.  Joint Committee on Health Care Laundry Guidelines. Guidelines for healthcare linen service. Mallandale, FL: Textile Rental Services Association of America, 1983; TRSA publication no. 71482.  Lauer JL, Battles DR, Vesley D. Decontaminating infectious laboratory waste by autoclaving. Appl Environ Microbiol 1982;44:690-4.  Levin N. Dialyzer re-use in a hospital. Dial and Transplant 1980;9(1): 40-6.  National AIDS Control Organisation. Manual of Hospital infection control, New Delhi, 1998;50-66  Park K. Hospital Waste Management. Park’s Textbook of Preventive and Social . M/s Banarasidas Bhanot Publications, New Delhi. 18th Edn, 2005: 595-598.  Pronovost P, Needham D, Berenholtz S, et al. (2006). "An intervention to decrease catheter-related bloodstream infections in the ICU". N. Engl. J. Med. 355 (26): 2725–32. doi:10.1056/NEJMoa061115. PMID 17192537.  Romeo AA. The economics of reuse. In: Reuse of disposable medical devices in the 1980's. Proceedings of International Conference on the Reuse of Disposable Medical Devices in the 1980's, The Institute for Health Policy Analysis, Georgetown University Medical Center, 1984 Mar 29-30. Washington, D.C.: Institute for Health Policy Analysis, 1984: 43-9.  Rutala WA, Sarubbi FA. Management of infectious waste from hospitals. Infect Control 1983;4:198-203.  Rutala WA, Stiegel MM, Sarubbi FA. Decontamination of laboratory microbiological waste by steam sterilization. Appl Environ Microbiol 1982;43:1311-6.  U.S. Department of Health and Human Services. Guidelines for construction and equipment of hospital and medical facilities. Washington: Government Printing Office, July 1984. DHHS publication No. (HRS-M-HF) 84-1.  Walter WG, Schillinger JE. Bacterial survival in laundered fabrics. Appl Microbiol 1975:29:368-73.  Weber DJ, Rutala WA (2006). "Use of germicides in the home and the healthcare setting: is there a relationship between germicide use and resistance?". Infect Control Hosp Epidemiol 27 (10): 1107–19. doi:10.1086/507964. PMID 17006819.  Wing AJ, Brunner FP, Brynger H, et al. Mortality and morbidity of reusing dialyzers. Br Med J 1978;2:853-5.

DISCLAIMER:

Flagship India provides the information contained herein in good faith, in compliance with the Occupational Safety and Health Act of 1970, but makes no representation as to its comprehensiveness or accuracy. This document is intended only as a guide to the appropriate precautionary handling of the material by a properly trained person using this product. Flagship India warrants that this product is of merchantable quality. The implied warranty of fitness for a particular purpose is limited to the extent the products are used for the purpose or uses described on the product's label or in any written instructions or materials distributed to the buyer by Flagship India and is hereby disclaimed should buyer use the products in a manner inconsistent with this uses or purposes described therein. In no event shall Flagship India be liable for any consequential, exemplary, or incidental damages incurred by buyer even if it has been advised of the possibility of such damages.

Registered Office: 61, Sukanta Sarani, Pragati-Pally, P.O: Italgacha, Kolkata, West-Bengal, India, Pin: 700079 Website: www.flagshipindia.in E-mail: [email protected]/ [email protected]